{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T08:10:40Z","timestamp":1760083840490,"version":"build-2065373602"},"reference-count":6,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Oncology Nursing"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.soncn.2017.05.002","type":"journal-article","created":{"date-parts":[[2017,7,5]],"date-time":"2017-07-05T11:30:21Z","timestamp":1499254221000},"page":"223-224","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Introduction"],"prefix":"10.1016","volume":"33","author":[{"given":"Beth","family":"Faiman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiffany","family":"Richards","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.soncn.2017.05.002_bib0010","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.soncn.2017.05.002_bib0015","doi-asserted-by":"crossref","first-page":"389","DOI":"10.6004\/jnccn.2016.0046","article-title":"NCCN guidelines insights: multiple myeloma, version 3.2016","volume":"14","author":"Anderson","year":"2016","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.soncn.2017.05.002_bib0020","doi-asserted-by":"crossref","first-page":"3294","DOI":"10.1182\/blood-2016-09-740787","article-title":"A Phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed\/refractory multiple myeloma","volume":"129","author":"Martin","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.soncn.2017.05.002_bib0025","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1182\/blood.V128.22.975.975","article-title":"Venetoclax combined with bortezomib and dexamethasone for patients with relapsed\/refractory multiple myeloma","volume":"128","author":"Moreau","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.soncn.2017.05.002_bib0030","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1182\/blood.V128.22.973.973","article-title":"Final results of phase 1 MMRC trial of selinexor, carfilzomib, and dexamethasone in relapsed\/refractory multiple myeloma (RRMM)","volume":"128","author":"Jakubowiak","year":"2016","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.soncn.2017.05.002_bib0035","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1182\/blood.V128.22.490.490","article-title":"Pembrolizumab, pomalidomide and low dose dexamethasone for relapsed\/refractory multiple myeloma","volume":"128","author":"Badros","year":"2017","journal-title":"Blood"}],"container-title":["Seminars in Oncology Nursing"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749208117300372?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749208117300372?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T07:32:35Z","timestamp":1760081555000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0749208117300372"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":6,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["S0749208117300372"],"URL":"https:\/\/doi.org\/10.1016\/j.soncn.2017.05.002","relation":{},"ISSN":["0749-2081"],"issn-type":[{"type":"print","value":"0749-2081"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Introduction","name":"articletitle","label":"Article Title"},{"value":"Seminars in Oncology Nursing","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.soncn.2017.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}